Published in PLoS Negl Trop Dis on February 14, 2013
VACCINES. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science (2015) 1.91
Site-specific, insertional inactivation of incA in Chlamydia trachomatis using a group II intron. PLoS One (2013) 1.11
Simultaneous transcriptional profiling of bacteria and their host cells. PLoS One (2013) 0.96
Influence of the tryptophan-indole-IFNγ axis on human genital Chlamydia trachomatis infection: role of vaginal co-infections. Front Cell Infect Microbiol (2014) 0.95
Pathogenesis of progressive scarring trachoma in Ethiopia and Tanzania and its implications for disease control: two cohort studies. PLoS Negl Trop Dis (2015) 0.93
Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research. Clin Microbiol Rev (2014) 0.92
Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye. Infect Immun (2014) 0.88
Towards a safe and effective chlamydial vaccine: lessons from the eye. Vaccine (2014) 0.87
Chlamydial polymorphic membrane proteins: regulation, function and potential vaccine candidates. Virulence (2015) 0.86
Poly(lactic acid)-poly(ethylene glycol) nanoparticles provide sustained delivery of a Chlamydia trachomatis recombinant MOMP peptide and potentiate systemic adaptive immune responses in mice. Nanomedicine (2014) 0.81
Conjunctival scarring in trachoma is associated with the HLA-C ligand of KIR and is exacerbated by heterozygosity at KIR2DL2/KIR2DL3. PLoS Negl Trop Dis (2014) 0.80
Fibroblasts profiling in scarring trachoma identifies IL-6 as a functional component of a fibroblast-macrophage pro-fibrotic and pro-inflammatory feedback loop. Sci Rep (2016) 0.79
Conjunctival fibrosis and the innate barriers to Chlamydia trachomatis intracellular infection: a genome wide association study. Sci Rep (2015) 0.79
Interventions for trachoma trichiasis. Cochrane Database Syst Rev (2015) 0.79
Assessment of a Novel Approach to Identify Trichiasis Cases Using Community Treatment Assistants in Tanzania. PLoS Negl Trop Dis (2015) 0.79
Doxycycline prevents matrix remodeling and contraction by trichiasis-derived conjunctival fibroblasts. Invest Ophthalmol Vis Sci (2013) 0.79
Hypothetical protein CT398 (CdsZ) interacts with σ(54) (RpoN)-holoenzyme and the type III secretion export apparatus in Chlamydia trachomatis. Protein Sci (2015) 0.78
Immunohistochemical Analysis of Scarring Trachoma Indicates Infiltration by Natural Killer and Undefined CD45 Negative Cells. PLoS Negl Trop Dis (2016) 0.78
A Coming of Age Story: Chlamydia in the Post-Genetic Era. Infect Immun (2015) 0.77
Intramuscular Immunisation with Chlamydial Proteins Induces Chlamydia trachomatis Specific Ocular Antibodies. PLoS One (2015) 0.77
Blinding Trachoma: Systematic Review of Rates and Risk Factors for Progressive Disease. PLoS Negl Trop Dis (2016) 0.76
Trachoma and Ocular Chlamydial Infection in the Era of Genomics. Mediators Inflamm (2015) 0.76
High Frequency of Latent Conjunctival C. trachomatis, M. hominis, and U. urealyticum Infections in Young Adults with Dry Eye Disease. J Ophthalmol (2014) 0.76
Engineering of obligate intracellular bacteria: progress, challenges and paradigms. Nat Rev Microbiol (2017) 0.75
A Probiotic Adjuvant Lactobacillus rhamnosus Enhances Specific Immune Responses after Ocular Mucosal Immunization with Chlamydial Polymorphic Membrane Protein C. PLoS One (2016) 0.75
Targeted Delivery of Amoxicillin to C. trachomatis by the Transferrin Iron Acquisition Pathway. PLoS One (2016) 0.75
Host-pathogen reorganisation during host cell entry by Chlamydia trachomatis. Microbes Infect (2015) 0.75
Setting Sights on Chlamydia Immunity's Central Paradigm: Can We Hit a Moving Target? Infect Immun (2017) 0.75
High frequency of latent Chlamydia trachomatis infection in patients with rhegmatogenous retinal detachment. Int J Ophthalmol (2016) 0.75
Evaluation of patients with dry eye disease for conjunctival Chlamydia trachomatis and Ureaplasma urealyticum. Int J Ophthalmol (2016) 0.75
Immunofibrogenic Gene Expression Patterns in Tanzanian Children with Ocular Chlamydia trachomatis Infection, Active Trachoma and Scarring: Baseline Results of a 4-Year Longitudinal Study. Front Cell Infect Microbiol (2017) 0.75
Global data on visual impairment in the year 2002. Bull World Health Organ (2004) 28.05
Cellular and molecular mechanisms of fibrosis. J Pathol (2008) 14.01
Of mice and not men: differences between mouse and human immunology. J Immunol (2004) 10.61
Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol (2004) 6.83
Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol (2004) 6.75
Trachoma: global magnitude of a preventable cause of blindness. Br J Ophthalmol (2008) 5.70
Secretion of proinflammatory cytokines by epithelial cells in response to Chlamydia infection suggests a central role for epithelial cells in chlamydial pathogenesis. J Clin Invest (1997) 4.51
Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Rev Immunol (2005) 4.50
Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein. J Exp Med (1989) 4.25
[Epidemiological surveillance of trachoma: evaluation and perspective]. Rev Int Trach Pathol Ocul Trop Subtrop Sante Publique (1992) 3.75
Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis (2005) 3.67
Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection. Infect Immun (1988) 3.55
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology (2010) 3.51
Importance of reinfection in the pathogenesis of trachoma. Rev Infect Dis (1986) 3.50
A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis (1997) 3.50
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov (2007) 3.36
Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest (2003) 3.04
Chlamydial disease pathogenesis. Ocular hypersensitivity elicited by a genus-specific 57-kD protein. J Exp Med (1989) 3.03
Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol (2009) 3.01
Development of a transformation system for Chlamydia trachomatis: restoration of glycogen biosynthesis by acquisition of a plasmid shuttle vector. PLoS Pathog (2011) 2.93
The cellular paradigm of chlamydial pathogenesis. Trends Microbiol (2003) 2.72
Trachoma vaccine studies in monkeys. Am J Ophthalmol (1967) 2.65
Resolution of chlamydial genital infection with antigen-specific T-lymphocyte lines. Infect Immun (1991) 2.62
Chronic chlamydial genital infection in congenitally athymic nude mice. Infect Immun (1985) 2.54
Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun (2000) 2.53
Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. J Immunol (2003) 2.44
A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis (2003) 2.36
Pathogenesis of trachoma: the stimulus for inflammation. J Immunol (1987) 2.34
Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect Immun (1997) 2.26
A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunol (2005) 2.26
Ocular delayed hypersensitivity: a pathogenetic mechanism of chlamydial-conjunctivitis in guinea pigs. Proc Natl Acad Sci U S A (1986) 2.24
Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci (2003) 2.20
An animal model of trachoma II. The importance of repeated reinfection. Invest Ophthalmol Vis Sci (1982) 2.16
Genome-wide identification of Chlamydia trachomatis antigens associated with trachomatous trichiasis. Invest Ophthalmol Vis Sci (2012) 2.13
Review of the evidence base for the 'F' and 'E' components of the SAFE strategy for trachoma control. Trop Med Int Health (2000) 2.12
Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis. J Exp Med (2010) 2.10
A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. Br J Ophthalmol (2005) 2.09
Epidemiology and control of trachoma: systematic review. Trop Med Int Health (2010) 2.01
Natural history of trachomatous scarring in The Gambia: results of a 12-year longitudinal follow-up. Ophthalmology (2001) 1.97
Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance. JAMA (1965) 1.97
Histopathologic changes related to fibrotic oviduct occlusion after genital tract infection of mice with Chlamydia muridarum. Sex Transm Dis (2005) 1.96
Association between antibody to the chlamydial heat-shock protein and tubal infertility. J Infect Dis (1993) 1.92
Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis (2010) 1.87
The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect (1999) 1.87
Longitudinal study of trachomatous trichiasis in the Gambia. Br J Ophthalmol (2002) 1.86
IL-17 and Th17 cells in tuberculosis. Cytokine Growth Factor Rev (2010) 1.86
Polymerase chain reaction for the detection of ocular chlamydial infection in trachoma-endemic communities. J Infect Dis (1994) 1.85
IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev (2010) 1.76
Chlamydia trachomatis persistence in vitro: an overview. J Infect Dis (2010) 1.74
Long term outcome of trichiasis surgery in the Gambia. Br J Ophthalmol (2005) 1.73
A live-attenuated chlamydial vaccine protects against trachoma in nonhuman primates. J Exp Med (2011) 1.70
The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up. PLoS Negl Trop Dis (2008) 1.69
The SAFE strategy for trachoma control: Using operational research for policy, planning and implementation. Bull World Health Organ (2006) 1.65
Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol (2011) 1.65
The role of Th17 cytokines in primary mucosal immunity. Cytokine Growth Factor Rev (2010) 1.64
Conjunctival scarring in trachoma is associated with depressed cell-mediated immune responses to chlamydial antigens. J Infect Dis (1993) 1.63
Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc Natl Acad Sci U S A (2006) 1.63
Risk factors for postsurgical trichiasis recurrence in a trachoma-endemic area. Invest Ophthalmol Vis Sci (2005) 1.62
Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun (2001) 1.61
Immunopathology of trachomatous conjunctivitis. Br J Ophthalmol (1989) 1.59
Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon- gamma. J Infect Dis (2005) 1.57
Progression of active trachoma to scarring in a cohort of Tanzanian children. Ophthalmic Epidemiol (2001) 1.54
IFN-gamma-mediated antimicrobial response. Indoleamine 2,3-dioxygenase-deficient mutant host cells no longer inhibit intracellular Chlamydia spp. or Toxoplasma growth. J Immunol (1993) 1.53
T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC); responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Clin Exp Immunol (1996) 1.48
Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res (2005) 1.48
Modeling the economic net benefit of a potential vaccination program against ocular infection with Chlamydia trachomatis. Vaccine (2004) 1.47
The long-term natural history of trachomatous trichiasis in the Gambia. Invest Ophthalmol Vis Sci (2006) 1.46
Scarring trachoma is associated with polymorphism in the tumor necrosis factor alpha (TNF-alpha) gene promoter and with elevated TNF-alpha levels in tear fluid. Infect Immun (1997) 1.45
The arrested immunity hypothesis and the epidemiology of chlamydia control. Sex Transm Dis (2008) 1.44
An animal model for cicatrizing trachoma. Invest Ophthalmol Vis Sci (1981) 1.44
Field trial of a monovalent and of a bivalent mineral oil adjuvant trachoma vaccine in Taiwan school children. Am J Ophthalmol (1967) 1.43
Blinding trachoma in postconflict southern Sudan. PLoS Med (2006) 1.42
Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol (2002) 1.41
Cytokine and fibrogenic gene expression in the conjunctivas of subjects from a Gambian community where trachoma is endemic. Infect Immun (2004) 1.41
Murine oviduct epithelial cell cytokine responses to Chlamydia muridarum infection include interleukin-12-p70 secretion. Infect Immun (2004) 1.41
Demonstration of delayed hypersensitivity in Chlamydia trachomatis salpingitis in monkeys: a pathogenic mechanism of tubal damage. J Infect Dis (1994) 1.36
Trachoma vaccine field trials in The Gambia. J Hyg (Lond) (1969) 1.33
Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun (2001) 1.28
The burden of trachoma in Ayod County of Southern Sudan. PLoS Negl Trop Dis (2008) 1.27
Incidence of trichiasis in a cohort of women with and without scarring. Int J Epidemiol (1999) 1.27
Subjects recovering from human ocular chlamydial infection have enhanced lymphoproliferative responses to chlamydial antigens compared with those of persistently diseased controls. Infect Immun (1995) 1.27
What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting. Invest Ophthalmol Vis Sci (2011) 1.26
Immune-mediated control of Chlamydia infection. Cell Microbiol (2007) 1.24
Evidence for a predominant proinflammatory conjunctival cytokine response in individuals with trachoma. Infect Immun (1996) 1.23
A coding polymorphism in matrix metalloproteinase 9 reduces risk of scarring sequelae of ocular Chlamydia trachomatis infection. BMC Med Genet (2006) 1.21
Field studies of protection from infection by experimental trachoma virus vaccine in preschool-aged children on Taiwan. Proc Soc Exp Biol Med (1963) 1.21
Expression of matrix metalloproteinases subsequent to urogenital Chlamydia muridarum infection of mice. Infect Immun (2005) 1.20
Bacterial infection and trachoma in the gambia: a case control study. Invest Ophthalmol Vis Sci (2007) 1.18
Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma. J Infect Dis (1998) 1.17
Systemic immunization with Hsp60 alters the development of chlamydial ocular disease. Invest Ophthalmol Vis Sci (1995) 1.16
Conjunctival expression of matrix metalloproteinase and proinflammatory cytokine genes after trichiasis surgery. Invest Ophthalmol Vis Sci (2010) 1.16
Conjunctival transcriptome in scarring trachoma. Infect Immun (2010) 1.15
Cellular immunity and Chlamydia genital infection: induction, recruitment, and effector mechanisms. Int Rev Immunol (2003) 1.14
Genetic variation at the TNF locus and the risk of severe sequelae of ocular Chlamydia trachomatis infection in Gambians. Genes Immun (2007) 1.13
Conjunctival FOXP3 expression in trachoma: do regulatory T cells have a role in human ocular Chlamydia trachomatis infection? PLoS Med (2006) 1.13
Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease. J Infect Dis (1997) 1.12
Effect of interferon on a primary conjunctival epithelial cell model of trachoma. Invest Ophthalmol Vis Sci (1991) 1.11
Expression of gelatinase B in trachomatous conjunctivitis. Br J Ophthalmol (2000) 1.11
Bacterial infection in scarring trachoma. Invest Ophthalmol Vis Sci (2011) 1.07
Human conjunctival transcriptome analysis reveals the prominence of innate defense in Chlamydia trachomatis infection. Infect Immun (2010) 1.07
Mass treatment with single-dose azithromycin for trachoma. N Engl J Med (2004) 5.30
Strategies for control of trachoma: observational study with quantitative PCR. Lancet (2003) 3.40
Two doses of azithromycin to eliminate trachoma in a Tanzanian community. N Engl J Med (2008) 2.71
Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet (2005) 2.62
Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet (2005) 2.50
Development and evaluation of a next-generation digital PCR diagnostic assay for ocular Chlamydia trachomatis infections. J Clin Microbiol (2013) 2.46
Whole-genome analysis of diverse Chlamydia trachomatis strains identifies phylogenetic relationships masked by current clinical typing. Nat Genet (2012) 2.44
Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophthalmol Vis Sci (2003) 2.20
Genome-wide identification of Chlamydia trachomatis antigens associated with trachomatous trichiasis. Invest Ophthalmol Vis Sci (2012) 2.13
Revealing the history of sheep domestication using retrovirus integrations. Science (2009) 2.12
Epidemiology and control of trachoma: systematic review. Trop Med Int Health (2010) 2.01
Active trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020? PLoS Negl Trop Dis (2009) 1.96
Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest Ophthalmol Vis Sci (2005) 1.94
Pathogenic diversity among Chlamydia trachomatis ocular strains in nonhuman primates is affected by subtle genomic variations. J Infect Dis (2008) 1.93
Trachoma prevalence and associated risk factors in the gambia and Tanzania: baseline results of a cluster randomised controlled trial. PLoS Negl Trop Dis (2010) 1.81
Co-evolution of genomes and plasmids within Chlamydia trachomatis and the emergence in Sweden of a new variant strain. BMC Genomics (2009) 1.78
Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities. PLoS Negl Trop Dis (2010) 1.67
Estimating household and community transmission of ocular Chlamydia trachomatis. PLoS Negl Trop Dis (2009) 1.52
Epidemiology of ocular surface squamous neoplasia in Africa. Trop Med Int Health (2013) 1.50
Biogeography of the ecosystems of the healthy human body. Genome Biol (2013) 1.48
Selective maturation of dendritic cells by Nippostrongylus brasiliensis-secreted proteins drives Th2 immune responses. Eur J Immunol (2004) 1.43
Cytokine and fibrogenic gene expression in the conjunctivas of subjects from a Gambian community where trachoma is endemic. Infect Immun (2004) 1.41
When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries. PLoS Negl Trop Dis (2009) 1.36
A diagnostics platform for the integrated mapping, monitoring, and surveillance of neglected tropical diseases: rationale and target product profiles. PLoS Negl Trop Dis (2012) 1.32
Trichiasis surgery in The Gambia: a 4-year prospective study. Invest Ophthalmol Vis Sci (2010) 1.27
The clinical phenotype of trachomatous trichiasis in Ethiopia: not all trichiasis is due to entropion. Invest Ophthalmol Vis Sci (2011) 1.26
A coding polymorphism in matrix metalloproteinase 9 reduces risk of scarring sequelae of ocular Chlamydia trachomatis infection. BMC Med Genet (2006) 1.21
Absorbable versus silk sutures for surgical treatment of trachomatous trichiasis in Ethiopia: a randomised controlled trial. PLoS Med (2011) 1.18
Conjunctival expression of matrix metalloproteinase and proinflammatory cytokine genes after trichiasis surgery. Invest Ophthalmol Vis Sci (2010) 1.16
Conjunctival transcriptome in scarring trachoma. Infect Immun (2010) 1.15
Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the Gambia. PLoS Negl Trop Dis (2013) 1.14
Trachomatous trichiasis and its management in endemic countries. Surv Ophthalmol (2012) 1.13
Conjunctival FOXP3 expression in trachoma: do regulatory T cells have a role in human ocular Chlamydia trachomatis infection? PLoS Med (2006) 1.13
The development of an age-structured model for trachoma transmission dynamics, pathogenesis and control. PLoS Negl Trop Dis (2009) 1.12
Clearing the backlog: trichiasis surgeon retention and productivity in northern Ethiopia. PLoS Negl Trop Dis (2011) 1.11
Surgery versus epilation for the treatment of minor trichiasis in Ethiopia: a randomised controlled noninferiority trial. PLoS Med (2011) 1.09
Analysis of flow cytometry data using an automatic processing tool. Cytometry A (2008) 1.09
Bacterial infection in scarring trachoma. Invest Ophthalmol Vis Sci (2011) 1.07
Human conjunctival transcriptome analysis reveals the prominence of innate defense in Chlamydia trachomatis infection. Infect Immun (2010) 1.07
Cataract surgery in Southern Ethiopia: distribution, rates and determinants of service provision. BMC Health Serv Res (2013) 1.05
Diagnostic accuracy of a prototype point-of-care test for ocular Chlamydia trachomatis under field conditions in The Gambia and Senegal. PLoS Negl Trop Dis (2011) 1.04
Chlamydia trachomatis ompA variants in trachoma: what do they tell us? PLoS Negl Trop Dis (2008) 1.03
Active trachoma is associated with increased conjunctival expression of IL17A and profibrotic cytokines. Infect Immun (2011) 1.02
Pathway-focused arrays reveal increased matrix metalloproteinase-7 (matrilysin) transcription in trachomatous trichiasis. Invest Ophthalmol Vis Sci (2010) 1.02
Conjunctival chlamydial 16S ribosomal RNA expression in trachoma: is chlamydial metabolic activity required for disease to develop? Clin Infect Dis (2006) 1.01
Targeting antibiotics to households for trachoma control. PLoS Negl Trop Dis (2010) 1.00
Phylogenetic analysis of Chlamydia trachomatis Tarp and correlation with clinical phenotype. Infect Immun (2010) 1.00
Association between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The Gambia. PLoS Negl Trop Dis (2013) 0.99
Epilation for trachomatous trichiasis and the risk of corneal opacification. Ophthalmology (2011) 0.98
Susceptibility to sequelae of human ocular chlamydial infection associated with allelic variation in IL10 cis-regulation. Hum Mol Genet (2007) 0.97
In vivo confocal microscopy in scarring trachoma. Ophthalmology (2011) 0.95
Innate immune responses and modified extracellular matrix regulation characterize bacterial infection and cellular/connective tissue changes in scarring trachoma. Infect Immun (2011) 0.93
Conjunctival MicroRNA expression in inflammatory trachomatous scarring. PLoS Negl Trop Dis (2013) 0.93
Why do people not attend for treatment for trachomatous trichiasis in Ethiopia? A study of barriers to surgery. PLoS Negl Trop Dis (2012) 0.93
The outcome of trachomatous trichiasis surgery in Ethiopia: risk factors for recurrence. PLoS Negl Trop Dis (2013) 0.93
Epilepsy in Tanzanian children: association with perinatal events and other risk factors. Epilepsia (2012) 0.93
Plasmid copy number and disease severity in naturally occurring ocular Chlamydia trachomatis infection. J Clin Microbiol (2013) 0.92
Using a nonparametric multilevel latent Markov model to evaluate diagnostics for trachoma. Am J Epidemiol (2013) 0.91
Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey. Virol J (2005) 0.87
Systemic effector and regulatory immune responses to chlamydial antigens in trachomatous trichiasis. Front Microbiol (2011) 0.86
Chlamydial positivity of nasal discharge at baseline is associated with ocular chlamydial positivity 2 months following azithromycin treatment. Invest Ophthalmol Vis Sci (2006) 0.86
Posterior segment eye disease in sub-Saharan Africa: review of recent population-based studies. Trop Med Int Health (2014) 0.85
In vivo confocal microscopy of trachoma in relation to normal tarsal conjunctiva. Ophthalmology (2010) 0.85
Eyescores: an open platform for secure electronic data and photographic evidence collection in ophthalmological field studies. Br J Ophthalmol (2012) 0.84
Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance. Curr Drug Targets (2016) 0.84
Post-operative recurrent trachomatous trichiasis is associated with increased conjunctival expression of S100A7 (psoriasin). PLoS Negl Trop Dis (2012) 0.83
In vivo confocal microscopy and histopathology of the conjunctiva in trachomatous scarring and normal tissue: a systematic comparison. Br J Ophthalmol (2013) 0.81
Quality assurance in trichiasis surgery: a methodology. Br J Ophthalmol (2010) 0.81
Co-morbidity of epilepsy in Tanzanian children: a community-based case-control study. Seizure (2011) 0.80
Will droplet digital PCR become the test of choice for detecting and quantifying ocular Chlamydia trachomatis infection? Maybe. Expert Rev Mol Diagn (2014) 0.80
Doxycycline prevents matrix remodeling and contraction by trichiasis-derived conjunctival fibroblasts. Invest Ophthalmol Vis Sci (2013) 0.79
Haptoglobin and sickle cell polymorphisms and risk of active trachoma in Gambian children. PLoS One (2010) 0.77
Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children. Trop Med Int Health (2014) 0.76
Ocular rhinosporidiosis mimicking conjunctival squamous papilloma in Kenya - a case report. BMC Ophthalmol (2014) 0.75
Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control. BMC Public Health (2014) 0.75
New DVD supports trachoma surgery training. Community Eye Health (2011) 0.75